Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof

Abstract

The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.

1 - 58 . (canceled)  
     
     
         59 . An antisense molecule comprising an oligonucleotide of length sufficient to modulate apoptosis, wherein said antisense oligonucleotide is complementary to a polynucleotide encoding CDN-1, CDN-2, CDN-3, CDN1Δ1, CDN1Δ2, or CDN1Δ3.  
     
     
         60 . The antisense compound of  claim 59 , which is targeted to a nucleic acid molecule encoding CDN-1 and which preferentially inhibits the expression of CDN-1.  
     
     
         61 . The antisense compound of  claim 59 , which promotes apoptosis.  
     
     
         62 . The antisense compound of  claim 59 , which inhibits apoptosis.  
     
     
         63 . A pharmaceutical composition comprising the antisense molecule of  claim 59  and a pharmaceutically acceptable carrier or diluent.  
     
     
         64 . A method of modulating apoptosis in a cell in a mammal diagnosed as having a proliferative disease, comprising administering to said mammal an antisense oligonucleotide of  claim 59 .  
     
     
         65 . The method of  claim 64 , wherein said mammal is a human.  
     
     
         66 . The method of  claim 64 , wherein said proliferative disease is cancer.  
     
     
         67 . A method to modulate apoptosis-induced cell death, comprising contacting an endogenous polynucleotide encoding SEQ ID NO:7 in a cell with an antisense polynucleotide that inhibits the expression of the polynucleotide encoding SEQ ID NO:7.  
     
     
         68 . The method of  claim 67 , wherein the antisense polynucleotide hybridizes under highly stringent conditions to a gene encoding SEQ ID NO:7.  
     
     
         69 . The method of  claim 67 , wherein the antisense polynucleotide is fully complementary to a polynucleotide encoding SEQ ID NO:7.  
     
     
         70 . The method of  claim 67 , wherein the antisense polynucleotide is fully complementary to a polynucleotide encoding a fragment of SEQ ID NO:7 lacking up to about the first 70 amino acids of SEQ ID NO:7, wherein the fragment modulates apoptosis in a cell.  
     
     
         71 . The method of  claim 67 , wherein the antisense polynucleotide is fully complementary to a polynucleotide encoding a fragment of SEQ ID NO:7 truncated after about amino acid position 112, wherein the fragment modulates apoptosis in a cell.  
     
     
         72 . The method of  claim 67 , wherein the antisense polynucleotide is fully complementary to a polynucleotide encoding an amino acid sequence that that is greater than 97% identical to SEQ ID NO:7, wherein the amino acid sequence modulates apoptosis in a cell.  
     
     
         73 . The method of  claim 67 , wherein apoptosis-induced cell death is increased in the cell in the presence of the polynucleotide as compared to in the absence of the polynucleotide.  
     
     
         74 . The method of  claim 67 , wherein the cell displays uncontrolled cell growth.  
     
     
         75 . The method of  claim 74 , wherein the cell is a cancer cell.  
     
     
         76 . The method of  claim 74 , wherein the cell is from a B cell lymphoma.